DFE Pharma

Carbon per million dollars of revenue. The legacy industry-standard reference (CDP, MSCI). Useful for cross-sector context, but distorted by margin — high-margin firms appear artificially efficient. Read alongside the operational and asset intensities for the full picture.

OpEx (operating expenditure) is the running cost of the business — staff, services, energy, materials. This shows how carbon-intensive operations are per million dollars of spend. Removes the margin distortion that revenue-based ratios introduce.

EVIC (Enterprise Value Including Cash) is the firm's total capital footprint — equity + debt + cash + minority interest. The EU's standard intensity measure (SFDR PAI 3) — answers: how much carbon does each million of capital deployed in this business produce?

PP&E (Property, Plant & Equipment) plus leased real-estate assets is the firm's physical infrastructure on the balance sheet. This shows the carbon intensity of that physical footprint — uses Scope 1+2+3 for consistency with the other headline intensities. Surfaces stranded-asset risk for asset-heavy firms.

All EU sites run on 100% green electricity as of 2024. Renewable energy nearly doubled in 2024 (70k→143k GJ, ~51% of total energy) driven by a biomass boiler at the new Cuddalore MCC capacity expansion in India. The old fossil-fuel boiler runs in parallel during transition and will be phased out by end of Q1-2025. Car lease policy was updated so every newly ordered vehicle in Germany and Netherlands is electric; full fleet electrification expected within 4 years.

DFE Pharma is aiming to prioritize emissions reduction through direct abatement, rather than using carbon credits. The firm plans to avoid the use of offsets to achieve 2030 reduction targets. Has invested in carbon-credit-sourced renewable energy projects in the interim until sufficient renewable sources are available. No removals (DAC, BECCS, etc.) disclosed.

• Fleet electrification (Germany & Netherlands)

  In 2024 the car lease policy was updated so every newly ordered vehicle in Germany and the Netherlands is electric. Whole fleet expected to be fully electrified within 4 years.

• Fossil oil phase-out at Cuddalore site

  In 2025 DFE Pharma will phase out the use of fossil oil at its Cuddalore site, marking a significant step in reducing Scope 1 emissions. Biomass boiler at the new MCC plant replaces the old fossil fuel boiler. All EU sites already on 100% green electricity for Scope 2.

• Sustainable packaging — 100% recyclable by 2030 and 25% plastic reduction

  Three-pronged circular packaging strategy: Recycle (100% recyclable packaging by 2030), Reduce (25% plastic reduction by 2030), Reuse (promote re-use across operations). Degree of packaging material separability improved from 77% (2021) to 92% (2024). Comprehensive database built to assess current status; active engagement with contract manufacturers to close data gaps.

• End-of-life and upstream/downstream transport (Scope 3 non-FLAG)

  SBTi-validated 42% reduction in Scope 3 emissions from purchased goods and services, upstream transportation and distribution, and end-of-life treatment of sold products by 2030 vs 2021 baseline. Non-FLAG Scope 3 represents ~25% of footprint with >90% of 'other' category being end-of-life and transport.

• FLAG/lactose supplier engagement (75% of Scope 3)

  FLAG emissions constitute 75% of Scope 3 and 74% of total carbon footprint, driven by dairy/lactose raw materials. 80% of Scope 3 calculation comes directly from farm-level data provided by lactose suppliers. SBTi 30.3% Scope 3 FLAG reduction target by 2030 vs 2021. Strategy relies on supplier collaboration to drive sustainable practices and zero-deforestation commitment by end-2025.